CEREVEL THERAPEUTICS HOLDINGS, INC.

(CERE)
  Report
Real-time Estimate Cboe BZX  -  05/17 03:04:44 pm EDT
25.45 USD   +0.97%
05/11Berenberg Bank Adjusts Cerevel Therapeutics Holdings Price Target to $44 From $46, Maintains Buy Rating
MT
05/10Cerevel Therapeutics Q1 Loss Widens
MT
05/10CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

JPMorgan Starts Cerevel Therapeutics Holdings at Overweight With $50 Price Target

01/05/2022 | 09:17am EDT


ę MT Newswires 2022
All news about CEREVEL THERAPEUTICS HOLDINGS, INC.
05/11Berenberg Bank Adjusts Cerevel Therapeutics Holdings Price Target to $44 From $46, Main..
MT
05/10Cerevel Therapeutics Q1 Loss Widens
MT
05/10CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial ..
AQ
05/10Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ende..
CI
05/10Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
AQ
04/18INSIDER SELL : Cerevel Therapeutics Holdings
MT
04/13Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update..
AQ
04/08SIRS 2022 PRESENTATION – EMRAC : Results From a Phase 1b Trial in Patients With Schi..
PU
04/06AAN 2022 POSTER - PHARMACOKINETICS, : Summary of Early Phase Clinical Studies
PU
04/06AAN 2022 PRESENTATION - DARIGABAT : pronounced antiepileptic activity in the mesial tempor..
PU
More news
Analyst Recommendations on CEREVEL THERAPEUTICS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -275 M - -
Net cash 2022 247 M - -
P/E ratio 2022 -13,3x
Yield 2022 -
Capitalization 3 737 M 3 737 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 228
Free-Float 81,4%
Chart CEREVEL THERAPEUTICS HOLDINGS, INC.
Duration : Period :
Cerevel Therapeutics Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CEREVEL THERAPEUTICS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 25,20 $
Average target price 42,86 $
Spread / Average Target 70,1%
EPS Revisions
Managers and Directors
N. Anthony Coles Executive Chairman & Chief Executive Officer
Abraham N. Ceesay President
Mark Bodenrader VP-Finance, Chief Financial & Accounting Officer
John Renger Chief Scientific Officer
Raymond Sanchez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CEREVEL THERAPEUTICS HOLDINGS, INC.-22.27%3 737
GILEAD SCIENCES, INC.-14.28%78 068
REGENERON PHARMACEUTICALS, INC.3.72%70 575
VERTEX PHARMACEUTICALS15.74%65 005
WUXI APPTEC CO., LTD.-16.67%42 275
BIONTECH SE-41.35%36 745